无创癌症诊断市场研究报告按测试类型（液体活检、成像测试、分子诊断、蛋白质生物标志物测试）、按癌症类型（乳腺癌、肺癌、结直肠癌、前列腺癌等）、按技术（下一代测序、聚合酶链反应、微阵列技术）、按分销渠道（医院药房、零售药房、在线药房、诊断实验室）和区域（北美、欧洲、南美洲、亚太地区、中东和非洲）- 2034 年预测
ID: MRFR/HC/32192-HCR | 100 Pages | Author: Rahul Gotadki| July 2025
| Report Attribute/Metric | Details |
| Market Size 2024 | 5.63 (USD Billion) |
| Market Size 2025 | 6.07 (USD Billion) |
| Market Size 2034 | 11.88 (USD Billion) |
| Compound Annual Growth Rate (CAGR) | 7.75 % (2025 - 2034) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2024 |
| Market Forecast Period | 2025 - 2034 |
| Historical Data | 2020 - 2024 |
| Market Forecast Units | USD billion |
| Key Companies Profiled | Exact Sciences, Biocept, Guardant Health, NantHealth, Illumina, Hertopia, GRAIL, Thermo Fisher Scientific, Cynvenio, Freenome, Myriad Genetics, Varian, Roche, OncoOne, Adverum Biotechnologies |
| Segments Covered | Test Type, Cancer Type, Technology, Distribution Channel, Regional |
| Key Market Opportunities | Early detection technologies, Liquid biopsy advancements, AI-driven diagnostic tools, Home-based testing solutions, Personalized treatment monitoring |
| Key Market Dynamics | Technological advancements, Increasing prevalence of cancer, Rising demand for early diagnosis, Favorable government initiatives, Growing awareness of noninvasive methods |
| Countries Covered | North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The Noninvasive Cancer Diagnostic Market is expected to be valued at 11.88 USD billion by 2034.
The market is projected to grow at a CAGR of 7.75% from 2025 to 2034.
North America is anticipated to have the largest market value of 4.0 USD billion by 2032.
The Liquid Biopsy segment is expected to reach a market value of 2.5 USD billion by 2032.
The Imaging Tests segment was valued at 1.5 USD billion in 2023.
Key players include Exact Sciences, Biocept, Guardant Health, and Illumina, among others.
Molecular Diagnostics is projected to reach a market size of 2.0 USD billion by 2032.
South America is forecasted to have a market value of 0.5 USD billion by 2032.
The Protein Biomarker Tests segment is projected to be worth 1.95 USD billion by 2032.
The APAC region is expected to reach a market size of 2.0 USD billion by 2032.
Comments
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
